Expression of X-linked inhibitor of apoptosis protein is a strong predictor of human prostate cancer recurrence

Clinical Cancer Research

Volumn 13, Issue 20, 2007, Pages 6056-6063

  Seligson, David B ^a   Hongo, Fumiya ^b   Huerta Yepez, Sara ^d   Mizutani, Yoichi ^c   Miki, Tsuneharu ^c   Yu, Hong ^a   Horvath, Steve ^a   Chia, David ^a   Goodglick, Lee ^a   Bonavida, Benjamin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KYOTO SECOND RED CROSS HOSPITAL   (Japan)

^c KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^d HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DNA; PROSTATE SPECIFIC ANTIGEN; PROTEIN P53; X LINKED INHIBITOR OF APOPTOSIS;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; CELL SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME BINDING; FEMALE; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROBABILITY; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RISK REDUCTION; TISSUE MICROARRAY; TREATMENT OUTCOME; VALIDATION PROCESS;

ADENOCARCINOMA; AGED; COHORT STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECURRENCE; TREATMENT OUTCOME; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 35948933880     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0960     Document Type: Article

References (51)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003;169:517-23.
3. Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005;61:1285-90.
4. Krajewska M, Krajewski S, Banares S, et al. Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Clin Cancer Res 2003;9:4914-25.
5. Bilim V, Kasahara T, Hara N, Takahashi K, Tomita Y. Role of XIAP in the malignant phenotype of transitional cell cancer (TCC) and therapeutic activity of XIAP antisense oligonucleotides against multi-drug-resistant TCC in vitro. Int J Cancer 2003;103:29-37.
6. Denmeade SR, Lin XS, Isaacs JT. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 1996;28:251-65.
7. Berezovskaya O, Schimmer AD, Glinskii AB, et al. Increased expression of apoptosis inhibitor protein XIAP contributes to anoikis resistance of circulating human prostate cancer metastasis precursor cells. Cancer Res 2005;65:2378-86.
8. Holcik M, Yeh C, Korneluk RG, Chow T. Translational upregulation of X-linked inhibitor of apoptosis (XIAP) increases resistance to radiation induced cell death. Oncogene 2000;19:4174-7.
9. Hammerman PS, Fox CJ, Thompson CB. Beginnings of a signal-transduction pathway for bioenergetic control of cell survival. Trends Biochem Sci 2004;29:586-92.
10. Green DR. Apoptotic pathways: ten minutes to dead. Cell 2005;121:671-4.
11. Cain K, Bratton SB, Cohen GM. The Apaf-1 apoptosome: a large caspase-activating complex. Biochimie 2002;84:203-14.
12. van Gurp M, Festjens N, van Loo G, Saelens X, Vandenabeele P. Mitochondrial intermembrane proteins in cell death. Biochem Biophys Res Commun 2003;304:487-97.
13. Uren AG, Pakusch M, Hawkins CJ, Puls KL, Vaux DL. Cloning and expression of apoptosis inhibitory protein homologs that function to inhibit apoptosis and/or bind tumor necrosis factor receptor-associated factors. Proc Natl Acad Sci U S A 1996;93:4974-8.
14. Deveraux QL, Takahashi R, Salvesen GS, Reed JC. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 1997;388:300-4.
15. Reed JC. The survivin saga goes in vivo. J Clin Invest 2001;108:965-9.
16. Holcik M, Gibson H, Korneluk RG. XIAP: apoptotic brake and promising therapeutic target. Apoptosis 2001;6:253-61.
17. Holcik M, Korneluk RG. XIAP, the guardian angel. Nat Rev Mol Cell Biol 2001;2:550-6.
18. Carter BZ, Gronda M, Wang Z, et al. Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acutemyeloid leukemia cells. Blood 2005;105:4043-50.
19. Nakagawa Y, Hasegawa M, Kurata M, et al. Expression of IAP-family proteins in adult acute mixed lineage leukemia (AMLL). Am J Hematol 2005;78:173-80.
20. Kashkar H, Haefs C, Shin H, et al. XIAP-mediated caspase inhibition in Hodgkin's lymphoma - derived B cells. J Exp Med 2003;198:341-7.
21. Schimmer AD, Welsh K, Pinilla C, et al. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 2004;5:25-35.
22. Schimmer AD. Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res 2004;64:7183-90.
23. Krajewska M, Kim H, Kim C, et al. Analysis of apoptosis protein expression in early-stage colorectal cancer suggests opportunities for new prognostic biomarkers. Clin Cancer Res 2005;11:5451-61.
24. Ferreira CG, van der Valk P, Span SW, et al. Assessment of IAP (inhibitor of apoptosis) proteins as predictors of response to chemotherapy in advanced non - small-cell lung cancer patients. Ann Oncol 2001;12:799-805.
25. Hofmann HS, Simm A, Hammer A, Silber RE, Bartling B. Expression of inhibitors of apoptosis (IAP) proteins in non - small cell human lung cancer. J Cancer Res Clin Oncol 2002;128:554-60.
26. Liu SS, Tsang BK, Cheung AN, et al. Anti-apoptotic proteins, apoptotic and proliferative parameters and their prognostic significance in cervical carcinoma. Eur J Cancer 2001;37:1104-10.
27. Shiraki K, Sugimoto K, Yamanaka Y, et al. Overexpression of X-linked inhibitor of apoptosis in human hepatocellular carcinoma. Int J Mol Med 2003;12:705-8.
28. Levkau B, Garton KJ, Ferri N, et al. xIAP induces cell-cycle arrest and activates nuclear factor-κB: new survival pathways disabled by caspase-mediated cleavage during apoptosis of human endothelial cells. Circ Res 2001;88:282-90.
29. Seligson D, Horvath S, Huerta-Yepez S, et al. Expression of transcription factor Yin Yang 1 in prostate cancer. Int J Oncol 2005;27:131-41.
30. Seligson DB, Horvath S, Shi T, et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005;435:1262-6.
31. Han KR, Seligson DB, Liu X, et al. Prostate stem cell antigen expression is associated with Gleason score, seminal vesicle invasion and capsular invasion in prostate cancer. J Urol 2004;171:1117-21.
32. Fleming ID, Cooper JS, Hensen DE, Hutter RVP, Kennedy BJ, Murphy GP. AJCC cancer staging manual. 5th ed. Philadelphia: Lippincott-Raven; 1997.
33. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974;111:58-64.
34. Young RH, Srigley JR, Amin MB, Ulbright TM, Cubilla A. Tumors of the prostate gland, seminal vesicle, male urethra, and penis. Atlas of tumor pathology. Washington, DC: Armed Forces Institute of Pathology; 2000.
35. Camp RL, Dolled-Filh art M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 2004;10:7252-9.
36. Pantuck AJ, Seligson DB, Klatte T, et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 2007;109:2257-67.
37. Dolled-Filhart M, McCabe A, Giltnane J, Cregger M, Camp RL, Rimm DL. Quantitative in situ analysis of β-catenin expression in breast cancer shows decreased expression is associated with poor outcome. Cancer Res 2006;66:5487-94.
38. Freedland SJ, Seligson DB, Liu AY, et al. Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer. Prostate 2003;55:71-80.
39. Liu X, Minin V, Huang Y, Seligson DB, Horvath S. Statistical methods for analyzing tissue microarray data. J Biopharm Stat 2004;14:671-85.
40. Tamm I, Kornblau SM, Segall H, et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res 2000;6:1796-803.
41. Tamm I, Richter S, Oltersdorf D, et al. High expression levels of X-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia. Clin Cancer Res 2004;10:3737-44.
42. Tamm I, Richter S, Scholz F, et al. XIAP expression correlates with monocytic differentiation in adult de novo AML: impact on prognosis. Hematol J 2004;5:489-95.
43. Fong WG, Liston P, Rajcan-Separovic E, St Jean M, Craig C, Korneluk RG. Expression and genetic analysis of XIAP-associated factor 1 (XAF1) in cancer cell lines. Genomics 2000;70:113-22.
44. Feng Z, Prentice R, Srivastava S. Researchissu es and strategies for genomic and proteomic biomarker discovery and validation: a statistical perspective. Pharmacogenomics 2004;5:709-19.
45. Maruvada P, Srivastava S. Joint National Cancer Institute-Food and Drug Administration workshop on researchs trategies, study designs, and statistical approaches to biomarker validation for cancer diagnosis and detection. Cancer Epidemiol Biomarkers Prev 2006;15:1078-82.
46. Maruvada P, Wang W, Wagner PD, Srivastava S. Biomarkers in molecular medicine: cancer detection and diagnosis. Biotechniques 2005;Suppl:9-15.
47. Ferreira CG, van der Valk P, Span SW, et al. Expression of X-linked inhibitor of apoptosis as a novel prognostic marker in radically resected non - small cell lung cancer patients. Clin Cancer Res 2001;7:2468-74.
48. Ramp U, Krieg T, Caliskan E, et al. XIAP expression is an independent prognostic marker in clear-cell renal carcinomas. Hum Pathol 2004;35:1022-8.
49. Ng CP, Bonavida B. X-linked inhibitor of apoptosis (XIAP) blocks Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of prostate cancer cells in the presence of mitochondrial activation: sensitization by overexpression of second mitochondria-derived activator of caspase/direct IAP-binding protein with low pl (SMAC/DIABLO). Mol Cancer Ther 2002;1:1051-8.
50. Du C, Fang M, Li Y, Li L, Wang X. SMAC, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000;102:33-42.
51. Verhagen AM, Ekert PG, Pakusch M, et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000;102:43-53.